Schonfeld Strategic Advisors LLC Jounce Therapeutics, Inc. Transaction History

Schonfeld Strategic Advisors LLC

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Nov 14, 2022	BUY	$2.73 - $4.92 $217,215 - $391,464	79,566 Added 51.42%	234,294 $549,000
Q2 2022 Aug 15, 2022	BUY	$2.8 - $7.67 $38,186 - $104,603	13,638 Added 9.67%	154,728 $469,000
Q1 2022 May 16, 2022	SELL	$6.01 - $8.54 $78,731 - $111,873	-13,100 Reduced 8.5%	141,090 $958,000
Q4 2021 Feb 14, 2022	BUY	$7.11 - $9.64 $265,956 - $360,593	37,406 Added 32.03%	154,190 $1.29 Million
Q3 2021 Nov 16, 2021	SELL	$5.04 - $8.73 $66,669 - $115,480	-13,228 Reduced 10.17%	116,784 $867,000
Q2 2021 Aug 16, 2021	SELL	$6.58 - $10.66 $518,504 - $840,008	-78,800 Reduced 37.74%	130,012 $885,000
Q1 2021 May 17, 2021	BUY	$6.73 - $13.87 $1.41 Million - $2.9 Million	208,812 New	208,812 $2.14 Million
Q2 2018 Aug 14, 2018	SELL	$7.27 - $21.88 $161,975 - $487,486	-22,280 Closed	0 $0
Q1 2018 May 15, 2018	BUY	$13.4 - $28.4 $298,552 - $632,752	22,280 New	22,280 $498,000

720K

Ticker JNCE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 51,694,200
Description
Jounce Therapeutics, Inc., a clinical-stage immunotherapy company, develops therapies for the treatment of cancer. The company develops vopratelimab, a clinical-stage monoclonal antibody, which is in Phase II clinical trial that binds to and activates the Inducible T cell CO-Stimulator, a protein on the surface of T cells found in various solid ...

Get notified when there are updates to the investment portfolio of Schonfeld Strategic Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Schonfeld Strategic Advisors LLC with notifications on news.